Literature DB >> 23220509

APTIMA HPV assay performance in women with atypical squamous cells of undetermined significance cytology results.

Mark H Stoler1, Thomas C Wright, Jack Cuzick, Janel Dockter, Jennifer L Reid, Damon Getman, Cristina Giachetti.   

Abstract

OBJECTIVE: The objective of the study was to determine the sensitivity and specificity of the APTIMA human papillomavirus (AHPV) assay for high-grade cervical intraepithelial neoplasia (CIN) in women 21 years old and older with atypical squamous cells of undetermined significance (ASC-US) cytology. STUDY
DESIGN: Women 21 years old and older with ASC-US cytology had colposcopy/biopsy and molecular human papillomavirus testing. Performance of the AHPV and Hybrid Capture 2 assays was compared with a clinical diagnosis of CIN grade 2, CIN grade 3, or adenocarcinoma in situ (CIN2 or greater).
RESULTS: Of 939 evaluable subjects, CIN2 or greater and CIN3 or greater prevalence was 9.7% and 4.4%, respectively. AHPV sensitivity and specificity was 86.8% and 62.9% for CIN2 or greater detection and 90.2% and 60.2% for CIN3 or greater, respectively. AHPV had a similar sensitivity to Hybrid Capture 2 but a significantly higher specificity (62.9% vs 55.8%, P < .001) for CIN2 or greater detection.
CONCLUSION: Among women with ASC-US cytology, detection of high-risk human papillomavirus E6/E7 oncogenic messenger ribonucleic acid is an effective triage method for colposcopy referral.
Copyright © 2013 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23220509     DOI: 10.1016/j.ajog.2012.12.003

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  15 in total

1.  Comparison of human papillomavirus detection by Aptima HPV and cobas HPV tests in a population of women referred for colposcopy following detection of atypical squamous cells of undetermined significance by Pap cytology.

Authors:  Philip E Castle; Barbara Eaton; Jennifer Reid; Damon Getman; Janel Dockter
Journal:  J Clin Microbiol       Date:  2015-02-04       Impact factor: 5.948

2.  Effect of preanalytical processing of ThinPrep specimens on detection of high-risk human papillomavirus by the Aptima HPV assay.

Authors:  Erik Munson; Elizabeth R Schroeder; Kevin C Ross; Connie Yauck; Theresa Bieganski; Robert D Amrhein; Maureen Napierala; April L Harkins
Journal:  J Clin Microbiol       Date:  2014-02-19       Impact factor: 5.948

3.  E6/E7 proteins are potential markers for the screening and diagnosis of cervical pre-cancerous lesions and cervical cancer in a Chinese population.

Authors:  Wen-Jing Shi; Hao Liu; Dan Wu; Zhen-Hua Tang; Yu-Chen Shen; Lin Guo
Journal:  Oncol Lett       Date:  2017-09-14       Impact factor: 2.967

4.  Comparison of commercial hybridization and automated transcription-mediated amplification modalities for detection of high-risk human papillomavirus nucleic acid.

Authors:  Erik Munson; Lynn Kroeger; Sandra Balzer; Robert Amrhein; Kimber L Munson; Maureen Napierala; Richard Hudspeth; Patrick J Dillon
Journal:  J Clin Microbiol       Date:  2013-11-06       Impact factor: 5.948

5.  The Aptima HPV assay fulfills the cross-sectional clinical and reproducibility criteria of international guidelines for human papillomavirus test requirements for cervical screening.

Authors:  D A M Heideman; A T Hesselink; F J van Kemenade; T Iftner; J Berkhof; F Topal; D Agard; C J L M Meijer; P J F Snijders
Journal:  J Clin Microbiol       Date:  2013-08-28       Impact factor: 5.948

6.  Separate analysis of human papillomavirus E6 and E7 messenger RNAs to predict cervical neoplasia progression.

Authors:  Shuling Liu; Takeo Minaguchi; Bouchra Lachkar; Shuang Zhang; Chenyang Xu; Yuri Tenjimbayashi; Ayumi Shikama; Nobutaka Tasaka; Azusa Akiyama; Manabu Sakurai; Sari Nakao; Hiroyuki Ochi; Mamiko Onuki; Koji Matsumoto; Hiroyuki Yoshikawa; Toyomi Satoh
Journal:  PLoS One       Date:  2018-02-21       Impact factor: 3.240

7.  Feasibility study of a human papillomavirus E6 and E7 oncoprotein test for the diagnosis of cervical precancer and cancer.

Authors:  Jin-Jun Zhang; Xin-Chun Cao; Xiang-Yu Zheng; Hai-Ying Wang; Yong-Wei Li
Journal:  J Int Med Res       Date:  2018-01-11       Impact factor: 1.671

8.  Secondary Prevention of Cervical Cancer: ASCO Resource-Stratified Clinical Practice Guideline.

Authors:  Jose Jeronimo; Philip E Castle; Sarah Temin; Lynette Denny; Vandana Gupta; Jane J Kim; Silvana Luciani; Daniel Murokora; Twalib Ngoma; Youlin Qiao; Michael Quinn; Rengaswamy Sankaranarayanan; Peter Sasieni; Kathleen M Schmeler; Surendra S Shastri
Journal:  J Glob Oncol       Date:  2016-10-12

9.  Disagreement between human papillomavirus assays: an unexpected challenge for the choice of an assay in primary cervical screening.

Authors:  Matejka Rebolj; Sarah Preisler; Ditte Møller Ejegod; Carsten Rygaard; Elsebeth Lynge; Jesper Bonde
Journal:  PLoS One       Date:  2014-01-20       Impact factor: 3.240

Review 10.  Clinical significance of human papillomavirus genotyping.

Authors:  Youn Jin Choi; Jong Sup Park
Journal:  J Gynecol Oncol       Date:  2016-03       Impact factor: 4.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.